CosterSShammoutAChaneyM, et al.Prophylactic enoxaparin dosing using anti-factor Xa levels in hepatic surgery patients: a pilot study. Am Surg. 2024;90(6):1760-1762. doi:10.1177/00031348241239926
2.
SikesLCharlesKAntiguaAPatelRImboywaSCherianP. Anti-factor Xa level monitoring for enoxaparin prophylaxis and treatment in high-risk patient groups. HCA Healthc J Med. 2023;4(2):105-109. doi:10.36518/2689-0216.1464
3.
ChanasTGibsonGLangenstroerE, et al.Multicenter study evaluating target attainment of anti-Factor Xa levels using various enoxaparin prophylactic dosing practices in adult trauma patients. Pharmacotherapy. 2024;44(3):258-267. doi:10.1002/phar.2904
4.
FlynnCBaldassarraJHamidiA. Enoxaparin is safe for the treatment of venous thromboembolisms in patients with renal dysfunction: a retrospective cohort study. Thromb Res. 2024;236:127-129. doi:10.1016/j.thromres.2024.02.027
5.
NemethAIsherwoodM. Safety and effectiveness of reduced dose versus standard dose enoxaparin venous thromboembolism prophylaxis in underweight medically ill patients. Hosp Pharm. 2023;58(2):178-182. doi:10.1177/00185787221123220
